UNSPSC 51434812: Orbutopril

This classification denotes an ace inhibitor with the molecular formula C20H34N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GFJ8659TQP, chemically known as (2s,3as,7as)-1-((s)-n-((s)-1-carboxypentyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester but generally known as orbutopril, which bears US NIH Compound Identifier 5745795. European Medicines Agency schedules Orbutopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09456MIG.

UNSPSC 51434812 Orbutopril (Commodity) represents a narrow pharmaceutical ingredient or formulation that state and local governments procure primarily as part of broader emergency medical services and pharmacy benefit programs. Recent solicitations show state and local bodies buying orbutopril and related advanced life support medications through competitive bidding and cooperative purchasing frameworks. The City of Tampa's Fire Rescue department bid for Advanced Life Support Medications (IFB 26P00188) in April 2026 included specific quantities of labetalol, epinephrine, adenosine, and diltiazem for emergency response use, with an estimated contract value of $40,000 and a one-year term plus renewal options. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription fulfillment capabilities, signaling state-level interest in optimizing pharmacy procurement channels outside traditional pharmacy benefit managers and wholesalers. Issuing bodies include city purchasing departments managing emergency services supply chains and state health agencies coordinating multi-jurisdiction pharmacy programs, with cooperative purchasing alliances like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) aggregating demand across state and local participants.

Recent activity concentrates in Florida and Texas, with broader multistate reach through cooperative vehicles. The Tampa Fire Rescue solicitation (response date April 8, 2026) required delivery within ten calendar days and maintained nine-month minimum expiration dates, with small local business enterprise set-asides offering 5 percent bid discounts. The MMCAP RFP (response deadline March 26, 2026) established a two-year contract for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026, with weighted evaluation favoring price competitiveness at 75 percent and requiring compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act certification. Neither the Tampa nor MMCAP solicitation specifically named orbutopril as a line item; the code's actual procurement activity under recent state and local opportunities remains unclear from available documentation.